Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EBIT (2021 - 2025)

Lyra Therapeutics has reported EBIT over the past 5 years, most recently at -$7.1 million for Q4 2025.

  • Quarterly results put EBIT at -$7.1 million for Q4 2025, up 37.61% from a year ago — trailing twelve months through Dec 2025 was -$31.0 million (up 67.8% YoY), and the annual figure for FY2025 was -$31.0 million, up 67.8%.
  • EBIT for Q4 2025 was -$7.1 million at Lyra Therapeutics, down from -$6.2 million in the prior quarter.
  • Over the last five years, EBIT for LYRA hit a ceiling of -$6.2 million in Q3 2025 and a floor of -$49.0 million in Q2 2024.
  • Median EBIT over the past 5 years was -$13.0 million (2021), compared with a mean of -$14.7 million.
  • Biggest five-year swings in EBIT: tumbled 196.76% in 2024 and later surged 81.98% in 2025.
  • Lyra Therapeutics' EBIT stood at -$13.6 million in 2021, then decreased by 11.12% to -$15.2 million in 2022, then fell by 8.72% to -$16.5 million in 2023, then skyrocketed by 30.76% to -$11.4 million in 2024, then soared by 37.61% to -$7.1 million in 2025.
  • The last three reported values for EBIT were -$7.1 million (Q4 2025), -$6.2 million (Q3 2025), and -$8.8 million (Q2 2025) per Business Quant data.